# 119-s-822: Scientific EXPERT Act of 2025

119-s-822, Scientific EXPERT Act of 2025, is a 119th Congress bill sponsored by Sen. Klobuchar, Amy [D-MN] (D-MN); status introduced; PRIA reads it as touching household money (as of 2025-12-21).

- Canonical: https://policyrisk.com/legislation/119-s-822
- As of: 2025-12-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-822
- Congress: 119
- Title: Scientific EXPERT Act of 2025
- Status: introduced
- Introduced: 2025-03-03
- Sponsor: Sen. Klobuchar, Amy [D-MN] (D-MN)
- Cosponsors: 1
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2025-12-21

## Summary

**Would create a formal, externally led forum to align science for rare disease drug development.** It would require the Reagan‑Udall Foundation to convene at least four meetings a year and would ask FDA reviewers to attend and publicly report whether meeting input influenced approval decisions. - Patients and families: Aims to clarify trial designs, endpoints, biomarkers, and patient selection for rare diseases, which may reduce uncertainty around developing and testing new treatments. - Researchers and drug developers: The Foundation would run a permanent steering committee and hold at least four science-focused meetings a year to build consensus on novel development approaches and standards. - FDA and public accountability: FDA review-division staff would attend every meeting, the Foundation must post transcripts and summaries within 180 days, and FDA would state when meeting input shaped an approval decision. *Would authorize $1.0 million per year for fiscal years 2025–2029, increasing federal outlays by that amount during those years.*

## Cosponsors (1)

- Sen. Wicker, Roger F. [R-MS] (R-MS), 2025-03-03T00:00:00.000Z

## Provisions PRIA read

- New rare-disease science meetings: benefit, medium. If enacted, the bill would require the Reagan-Udall Foundation to run externally led science-focused drug development meetings on rare diseases. The Foundation would hold at least four meetings each year, each on a different rare disease or group. FDA review staff must participate in every meeting.…
- Federal funding for rare disease meetings: benefit, low. If enacted, the bill would authorize $1 million a year for fiscal years 2025 through 2029 to support Foundation planning and operation of the meetings. It would also authorize $1 million a year for fiscal years 2025 through 2029 to support reporting and public statements about how meetings influenc…
- Limits on meeting legal effects: mixed, low. If enacted, the bill would say these meetings do not create legal rights to consultation. It would not force FDA to join meetings run by other groups. The bill would not change trade secret or other confidentiality protections or increase the number of drug review cycles. Other third parties would…

## Related bills

- 119-s-2296: National Defense Authorization Act for Fiscal Year 2026
- 119-s-4784: National Defense Authorization Act for Fiscal Year 2027
- 119-s-3923: Weather Research and Forecasting Innovation Reauthorization Act of 2026
- 119-s-1541: SHIPS for America Act of 2025
- 119-s-5071: Children's Safe Welcome Act of 2026
- 119-s-2838: Protecting Our Democracy Act

## Sources
- [119-s-822 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/822)

## Related
- [119-s-2296: National Defense Authorization Act for Fiscal Year 2026](https://policyrisk.com/legislation/119-s-2296)
- [119-s-4784: National Defense Authorization Act for Fiscal Year 2027](https://policyrisk.com/legislation/119-s-4784)
- [119-s-3923: Weather Research and Forecasting Innovation Reauthorization Act of 2026](https://policyrisk.com/legislation/119-s-3923)
- [119-s-1541: SHIPS for America Act of 2025](https://policyrisk.com/legislation/119-s-1541)
- [119-s-5071: Children's Safe Welcome Act of 2026](https://policyrisk.com/legislation/119-s-5071)
- [119-s-2838: Protecting Our Democracy Act](https://policyrisk.com/legislation/119-s-2838)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-822 (as of 2025-12-21).